Intellectual Property

Critical to our business success is the ability to obtain and maintain enforceable intellectual property rights adequate to protect our innovations for candidate drugs and our drug discovery and platform technologies to provide exclusivity and licensable rights. Additionally, our success also depends on operating without infringing or otherwise violating the proprietary rights of others and dissuading others from infringing our own intellectual property.

Our current patent portfolio comprises over 66 patent families including approximately 326 issued patents and 214 patent applications, covering key territories, including the U.S., UK, Germany, France, Canada, China and Japan. Our portfolio comprises patents that we own or license exclusively, or as a consequence from collaborations and historical dealings jointly with third parties.